生物
细胞毒性T细胞
癌症研究
CD8型
T细胞受体
癌症
膀胱癌
免疫疗法
T细胞
主要组织相容性复合体
白细胞介素21
免疫学
抗原
免疫系统
体外
遗传学
作者
David Y. Oh,Serena S. Kwek,Siddharth S. Raju,Tony Li,Elizabeth E. McCarthy,Eric D. Chow,Dvir Aran,Arielle Ilano,Chien-Chun Steven Pai,Chiara Rancan,Kathryn M. Allaire,Arun Burra,Yang Sun,Matthew H. Spitzer,Serghei Mangul,Sima P. Porten,Maxwell V. Meng,Terence W. Friedlander,Chun Ye,Lawrence Fong
出处
期刊:Cell
[Elsevier]
日期:2020-06-01
卷期号:181 (7): 1612-1625.e13
被引量:503
标识
DOI:10.1016/j.cell.2020.05.017
摘要
Responses to anti-PD-1 immunotherapy occur but are infrequent in bladder cancer. The specific T cells that mediate tumor rejection are unknown. T cells from human bladder tumors and non-malignant tissue were assessed with single-cell RNA and paired T cell receptor (TCR) sequencing of 30,604 T cells from 7 patients. We find that the states and repertoires of CD8+ T cells are not distinct in tumors compared with non-malignant tissues. In contrast, single-cell analysis of CD4+ T cells demonstrates several tumor-specific states, including multiple distinct states of regulatory T cells. Surprisingly, we also find multiple cytotoxic CD4+ T cell states that are clonally expanded. These CD4+ T cells can kill autologous tumors in an MHC class II-dependent fashion and are suppressed by regulatory T cells. Further, a gene signature of cytotoxic CD4+ T cells in tumors predicts a clinical response in 244 metastatic bladder cancer patients treated with anti-PD-L1.
科研通智能强力驱动
Strongly Powered by AbleSci AI